Celldex Therapeutics
CLDX
139 hedge funds and large institutions have $283M invested in Celldex Therapeutics in 2016 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 45 reducing their positions, and 18 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 45
1% less funds holding
Funds holding: 141 → 139 (-2)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
17% less call options, than puts
Call options by funds: $2.24M | Put options by funds: $2.7M
19% less capital invested
Capital invested by funds: $348M → $283M (-$65.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NI
Numeric Investors
Boston,
Massachusetts
|
+$4.38M |
| 2 |
D.E. Shaw & Co
New York
|
+$4.36M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.88M |
| 4 |
Renaissance Technologies
New York
|
+$2M |
| 5 |
Millennium Management
New York
|
+$1.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OppenheimerFunds
New York
|
-$40.2M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$9.77M |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$3.85M |
| 4 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
-$3.4M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$2.34M |
CLDX Hedge Fund Activity: Q3 2016 in Review
139 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q3 2016, worth a combined $283M — down 19% from $348M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CLDX and 16 opened new positions — a net loss of 2 holders — while 45 trimmed existing stakes and 45 added.
The largest buyer was Numeric Investors, adding an estimated $4.38M. The largest seller was OppenheimerFunds, exiting entirely with an estimated $40.2M sold.
- 139 institutional investors held Celldex Therapeutics (CLDX) as of Q3 2016, down from 141 in Q2 2016.
- Funds reported $283M of Celldex Therapeutics stock for Q3 2016, down 19% quarter-over-quarter.
- 16 funds opened new Celldex Therapeutics positions in Q3 2016 and 18 closed out, a net change of -2 holders.
- The largest Celldex Therapeutics buyer in Q3 2016 was Numeric Investors, an estimated $4.38M added.
- The largest Celldex Therapeutics seller in Q3 2016 was OppenheimerFunds, an estimated $40.2M sold.
Based on aggregated 13F filings for Q3 2016.